Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.07 USD | -1.60% | -5.91% | -6.46% |
05-23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
05-23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.46% | 1.51B | |
+16.34% | 79.03B | |
+8.65% | 8.78B | |
-16.33% | 4.83B | |
+51.22% | 4.65B | |
+2.18% | 3.89B | |
+20.51% | 2.34B | |
-26.79% | 2.18B | |
+15.12% | 2.11B | |
-36.56% | 2B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals Reports Higher Q1 Earnings, Revenue; Affirms 2022 Revenue Guidance